The antibody 2E5 reacts with an extracellular epitope within C-terminal half of TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues.
No Cross-Reactivity
Mouse
Cross-Reactivity (Details)
Human
Purification
Purified by protein-A affinity chromatography.
Purity
> 95 % (by SDS-PAGE)
Endotoxin Level
Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
Immunogen
Recombinant soluble fragment (aa 95-281) of human TRAIL.
TNFSF10
Reactivity: Human
WB
Host: Mouse
Polyclonal
unconjugated
Application Notes
Functional application: The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. Flow cytometry: Recommended dilution: 1-10 μg/mL.
Restrictions
For Research Use only
Concentration
1 mg/mL
Buffer
Phosphate buffered saline (PBS), pH 7.4
Preservative
Azide free
Storage
4 °C
Storage Comment
Store at 2-8°C. Do not freeze.
Plasilova, Zivny, Jelinek, Neuwirtova, Cermak, Necas, Andera, Stopka: "TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors." in: Leukemia, Vol. 16, Issue 1, pp. 67-73, (2002) (PubMed).
Target
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
TNF superfamily member 10,Human CD253 / TRAIL (TNF-related apoptosis inducing ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).,TRAIL, Apo-2 ligand, Apo-2L, TNFSF10, APO2L, TNLG6A